Mayotte Takes Emergency Action Against Chikungunya Outbreak

The Department of Mayotte, an overseas department of France, recently announced that, due to the first indigenous (local) case of chikungunya on the island, health authorities are activating level 2A of the ORSEC (emergency) plan.

This decision will increase surveillance of the epidemiological situation and measures to prevent more active viral (virus) circulation by mosquitoes in the territory.

As of April 7, 2025, Mayotte has reported four chikungunya cases this year.

As a reminder, about 900 miles away, Reunion Island has been facing a chikungunya epidemic, with 13,594 cases, including two related fatalities, since August 2024.

Mayotte's Regional Health Agency says all travelers to and from Reunion Island should protect themselves from mosquito bites.

Mayotte is located between Africa's east coast and Madagascar, one of France's 18 regions.

To protect people on Reunion, the local government has started vaccinating 40,000 residents with a U.S. FDA-approved vaccine.

Valneva SE's IXCHIQ® Chikungunya vaccine is commercially available in the U.S. and recommended for travelers to endemic areas in 2025.